Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. (VTYX): 5 pipeline candidates · ~32 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
32.2 months
D/E 0.10 · 0% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for Ventyx Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.0B
Cash
$32.9M
Quarterly Burn
$17.5M
Runway
32.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| abenacianine | Phase 3 |
| tamuzimod | Phase 2 |
| vtx2735 | Phase 2 |
| vtx3232 | Phase 2 |
| vtx958 | Phase 2 |
Frequently asked questions
How many drug candidates are in Ventyx Biosciences, Inc.'s pipeline?
Ventyx Biosciences, Inc. (VTYX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Ventyx Biosciences, Inc.'s lead drug candidate?
Ventyx Biosciences, Inc.'s most advanced tracked candidate is abenacianine (Phase 3) for Lung Cancer.
What is Ventyx Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Ventyx Biosciences, Inc. has approximately 32.2 months of cash runway.
What is Ventyx Biosciences, Inc.'s market capitalization?
Ventyx Biosciences, Inc.'s market capitalization is approximately $1.0B.
Who is the CEO of Ventyx Biosciences, Inc.?
Raju Mohan, Ph.D. is the chief executive officer of Ventyx Biosciences, Inc. (VTYX).
Get the full picture on Ventyx Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.